W B Knight
Overview
Explore the profile of W B Knight including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
832
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
TOMLINSON J, Butler B, Frezza J, Harris C, Smith A, Knight W
J Automat Chem
. 2008 Oct;
20(3):83-5.
PMID: 18924821
In 1996 and 1997, Glaxo Wellcome's US Research division planned and established their second generation research strategy. An important aspect of the strategy entailed development of two automated screening sites...
2.
Rusnak D, Lackey K, Affleck K, Wood E, Alligood K, Rhodes N, et al.
Mol Cancer Ther
. 2002 Dec;
1(2):85-94.
PMID: 12467226
The epidermal growth factor receptor (EGFR) and ErbB-2 transmembrane tyrosine kinases are currently being targeted by various mechanisms in the treatment of cancer. GW2016 is a potent inhibitor of the...
3.
Rusnak D, Affleck K, Cockerill S, Stubberfield C, Harris R, Page M, et al.
Cancer Res
. 2001 Oct;
61(19):7196-203.
PMID: 11585755
The type I receptor tyrosine kinases constitute a family of transmembrane proteins involved in various aspects of cell growth and survival and have been implicated in the initiation and progression...
4.
Vicentini C, Guarneri M, Andrisano V, Guccione S, Langer T, Marschhofer R, et al.
J Enzyme Inhib
. 2001 Aug;
16(1):15-34.
PMID: 11496832
As a part of an investigation on molecular hybrids as new serine protease inhibitors, the pyrazolo [4,3-c][1,2,5]oxadiazin-3(5H)-one ring system was selected as a model of potential mechanism-based inhibitors. Due to...
5.
Tian G, Cory M, Smith A, Knight W
Biochemistry
. 2001 Jun;
40(24):7084-91.
PMID: 11401553
The kinetic mechanisms for the inhibition of pp60(c-src) tyrosine kinase (Src TK) by 4-anilinoquinazolines, an important class of chemicals as protein kinase inhibitors, were investigated. 4-Anilinoquinazolines with a bulky group...
6.
Thomas J, Ellis B, Boerner R, Knight W, White 2nd G, Schaller M
J Biol Chem
. 1998 Feb;
273(1):577-83.
PMID: 9417118
Intramolecular SH2 and SH3 interactions mediate enzymatic repression of the Src kinases. One mechanism of activation is disruption of these interactions by the formation of higher affinity SH2 and SH3...
7.
Ades L, Knight W, Byard R, Bateman J, Esquivel J, Mee R, et al.
Am J Med Genet
. 1996 Dec;
66(3):289-99.
PMID: 8985490
We describe the clinical, histopathologic, and angiographic findings in four children with congenital abnormalities of the great vessels of unknown cause, comprising either single or multiple arterial aneurysms, aortic/arterial dilatation,...
8.
Boerner R, Kassel D, Barker S, Ellis B, DeLacy P, Knight W
Biochemistry
. 1996 Jul;
35(29):9519-25.
PMID: 8755732
Rapid digestion of pp60c-src tyrosine kinase (src TK) in combination with electrospray ionization mass spectrometry enabled the determination of the time course for autophosphorylation of three tyrosine sites (Y338, Y419,...
9.
Olszewski J, Moore V, McDonnell J, Williams H, Saphos C, Green B, et al.
Connect Tissue Res
. 1996 Jan;
33(4):291-9.
PMID: 8834447
The objective of this study was to compare the specificity and potency of recombinant human SLN-1 (rhSLN) and human leukocyte elastase (HLE) as proteoglycan (PG)-degrading enzymes after intraarticular injection into...
10.
Boerner R, Barker S, Knight W
Biochemistry
. 1995 Dec;
34(50):16419-23.
PMID: 8845369
The kinetic mechanism of the pp60c-src tyrosine kinase (src TK) reaction was investigated in the forward and reverse directions. In the forward direction, initial velocities obtained by varying ATP and...